Almirall's Thermigen unit in distribution deal with Sinclair

Almirall (ALM: MC) has signed, through its recently-acquired Dallas, USA-based subsidiary Thermigen (The Pharma Letter February 1), an exclusive US strategic marketing collaboration agreement for Silhouette Instalift with Sinclair Pharma (LSE: SPH), a UK specialty pharma company.

The US distribution agreement with Thermi for Silhouette Instalift will give immediate access to the largest single aesthetics market in the world, according to Almirall, which is Spain’s biggest drugmaker. This is the second aesthetics deal for the Spanish firm, following its collaboration with Bicosome (TPL May 19).

Sinclair estimates that over 250 Instalift procedures have been performed to-date and through the activities of independent Continuing Medical Education providers (CME) and meetings over 2000 physicians have learned about InstaLift from their peers and over 50 have already received up to date aesthetic education and training in broad based programs that include InstaLift.  These initial efforts provide the Thermi team with a well-established group of thought leading physicians as the foundation for their launch efforts.